» Articles » PMID: 39661100

Prescription Drug Use in Danish Children and Adolescents 2005-2023

Overview
Journal Eur J Epidemiol
Specialty Public Health
Date 2024 Dec 11
PMID 39661100
Authors
Affiliations
Soon will be listed here.
Abstract

Continuous monitoring of pediatric drug utilization is important for ensuring rational use and prioritizing research. This study provides an overview of pediatric prescription drug use among Danish children and adolescents from 2005-2023. Using Danish nationwide individual-level dispensing data, we identified all redeemed prescriptions for individuals < 18 years from January 2005-December 2023. We computed overall annual prevalence proportions of users and mean number of prescriptions per child. For all non-antibiotic drugs, we further determined the quantity of drug use measured in defined daily doses (DDDs) and stratified all analyses by age and Anatomical Therapeutic Chemical classification first and forth level. During the study period, the overall yearly prevalence of prescription drug use decreased due to reductions in antibiotic prescribing. When antibiotic prescriptions were disregarded, the prevalence of children with at least one prescription increased from 38% in 2005 to 42% in 2023, while the mean number of prescriptions and DDDs increased from 1.2 prescriptions per child and 51.2 million DDDs in 2005 to 1.5 prescriptions per child and 76.5 million DDDs in 2023. This increase was primarily driven by prescribing of central nervous system drugs to adolescents 12-17 years, with a substantial increase in centrally acting sympathomimetics and melatonin use. Overall pediatric drug prescribing is decreasing due to reduced antibiotic use. Non-antibiotic drug use is, however, rising, especially among adolescents and notably for psychotropic drugs. These findings underscore the importance of ongoing monitoring and call for further research into underlying causes and prescription practices for psychotropics.

References
1.
Dunne J, Rodriguez W, Murphy M, Beasley B, Burckart G, Filie J . Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics. 2011; 128(5):e1242-9. DOI: 10.1542/peds.2010-3487. View

2.
Samuels S, Park K, Bhatt-Mehta V, Sun H, Mulugeta Y, Yao L . Pediatric Efficacy Extrapolation in Drug Development Submitted to the US Food and Drug Administration 2015-2020. J Clin Pharmacol. 2022; 63(3):307-313. DOI: 10.1002/jcph.2160. View

3.
Hoon D, Taylor M, Kapadia P, Gerhard T, Strom B, Horton D . Trends in Off-Label Drug Use in Ambulatory Settings: 2006-2015. Pediatrics. 2019; 144(4). PMC: 7286122. DOI: 10.1542/peds.2019-0896. View

4.
Palmaro A, Bissuel R, Renaud N, Durrieu G, Escourrou B, Oustric S . Off-label prescribing in pediatric outpatients. Pediatrics. 2014; 135(1):49-58. DOI: 10.1542/peds.2014-0764. View

5.
Olsson J, Kimland E, Pettersson S, Odlind V . Paediatric drug use with focus on off-label prescriptions in Swedish outpatient care--a nationwide study. Acta Paediatr. 2011; 100(9):1272-5. PMC: 3187868. DOI: 10.1111/j.1651-2227.2011.02287.x. View